The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease by unknown
Li and Fei Respiratory Research 2013, 14:140
http://respiratory-research.com/content/14/1/140RESEARCH Open AccessThe unique alterations of hippocampus and
cognitive impairment in chronic obstructive
pulmonary disease
Jing Li and Guang-He Fei*Abstract
Background: Cognitive impairment has been found in chronic obstructive pulmonary disease (COPD) patients.
However, the structural alteration of the brain and underlying mechanisms are poorly understood.
Methods: Thirty-seven mild-to-moderate COPD patients, forty-eight severe COPD patients, and thirty-one control
subjects were recruited for cognitive test and neuroimaging studies. Serum levels of S100B,pulmonary function and
arterial blood gas levels were also evaluated in each subject.
Results: The hippocampal volume was significantly smaller in COPD patients compared to the control group. It is
positively correlated with a mini mental state examination (MMSE) score, SaO2 in mild-to-moderate COPD patients,
the levels of PaO2 in both mild-to-moderate and severe COPD patients. Higher S100B concentrations were observed
in mild-to-moderate COPD patients, while the highest S100B level was found in severe COPD patients when compared
to the control subjects. S100B levels are negatively associated with MMSE in both mild-to-moderate and severe COPD
patients and also negatively associated with the hippocampal volume in the total COPD patients.
Conclusions: Hippocampal atrophy based on quantitative assessment by magnetic resonance imaging does occur in
COPD patients, which may be associated with cognitive dysfunction and the most prevalent mechanism accountable
for hippocampal atrophy is chronic hypoxemia in COPD. Higher serum S100B levels may be peripheral biochemical
marker for cognitive impairment in COPD.
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Chronic obstructive pulmonary disease (COPD) is a pri-
mary airway inflammatory disease characterized by irre-
versible airflow limitation which results in hypoxemia
and hypercapnia. Meanwhile, it is also realized as a
complex multi-component disorder [1-4]. Cognitive im-
pairment has been found as one of the important extra-
pulmonary manifestation in patients with COPD [5-8].
In our previous study, we also found that cognitive dys-
function is associated with the classification of disease
severity [9]. However, whether some structural brain ab-
normalities are associated with poor cognitive perfor-
mances in COPD patients has not been fully explored.* Correspondence: guanghefei@126.com
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stated.The hippocampus which is located inside the medial
temporal lobe is a major component of the brain. It con-
tains two main interlocking parts (Ammon’s horn and
the dentate gyrus) and four histological divisions (cornu
ammonis 1 (CA1), CA2, CA3 and CA4). It plays a key
role in cognitive function and is particularly vulnerable
to the adverse effects of hypoxemia. As morphologic evi-
dence, magnetic resonance imaging (MRI) studies de-
monstrated that hippocampal atrophy is a diagnostic
biomarker for cognitive impairment [10,11]. Lower hip-
pocampal volume detected by MRI was a consistent
finding in mild cognitive impairment (MCI) and Alzhei-
mer’s disease [12,13]. To our knowledge, quantitative as-
sessment of the hippocampal region in COPD patients
has not yet been carried out, although there may be
a pattern of cognitive impairment specific to COPD
patients [8]. Therefore, the question arises as to whether. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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occur in COPD patients.
S100B, a member of the S100 protein family, is a
calcium-binding protein [14]. It is a brain derived pro-
tein implicated in CNS function generally and the hippo-
campus in particular [15]. Increased S100B levels are
observed in patients suffering from chronic neurodegene-
rative disorders such Alzheimer’s disease [16-18]. Further-
more, it is also studied as a peripheral biochemical marker
for cognitive ability [19]. Previous studies showed that
serum S100B levels were negatively correlated with MMSE
scores [20]. However, little data exists with regards to this
biomarker and cognitive performances in COPD patients.
In this study, we evaluated the hippocampal volumes
and cognitive performances in COPD patients at differ-
ent stages. In order to explore the possible mechanisms
involved in this pathology, we also investigated the asso-
ciations between the hippocampal volume, pulmonary




Eighty-five subjects, including thirty-seven mild-to-moderate
COPD patients, forty-eight severe COPD patients, and
thirty-one control subjects participated in the present
study. The three groups were matched for age, sex, edu-
cation level, body mass index (BMI), smoking status,
and cardiovascular disease. The COPD patients came
from the First Affiliated Hospital of Anhui Medical Uni-
versity. The diagnoses and classification of COPD were
made according to the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) 2011 guidelines [21].
All patients were clinically stable for ≥8 weeks and wereTable 1 Demographic characteristics in the control group and
Characteristic Control group (n = 31) Mild-to-mode







Current smoker 34.13 ± 12.11
Ex-smoker 27.25 ± 8.68
Education, years 8.07 ± 4.97
BMI, kg/m2 22.51 ± 2.67
Cardiovascular disease, % 38.71
Data are presented as means ± SD, except where indicated otherwise. Cardiovascula
failure. BMI = Body Mass Index.
a: One-way analysis of variance. b: Analysis of Chi-Square test.treated only with necessary medications: antibiotics, β2
adrenoreceptor agonists, ambroxol, and oxygen therapy.
Exclusion criteria were: Dementia, sleep disorders, ob-
structive sleep apnoea (OSA), chronic kidney disease,
liver disease, head injury, psychiatric disorders (depres-
sion, anxiety disorders, schizophrenia, or alcohol abuse),
and usage of any drugs which might affect cognitive per-
formance. All participants were assessed by a complete
physical examination by three raters including a respira-
tory physician, a cardiologist, and a neuropsychologist. All
subjects had given written informed consent to participate
and were told of the possible risks in the study; the proto-
col was approved by the Human Investigation Committee
of Anhui Medical University. The experiment was per-
formed from November 1, 2011 to January 15, 2013.
Arterial blood gas analysis
Arterial blood gas analysis was performed by using Stat
Profile Critical Care Xpress (Nova Biomedical, Waltham,
Mass., USA). The arterial oxygen tension (PaO2), arterial
carbon dioxide tension (PaCO2) and blood oxygen satur-
ation (SaO2) was evaluated for all subjects while they
breathed room air in the supine position.
Pulmonary function tests
Standardized pulmonary function tests were performed
using a dry spirometer device (Erich Jaeger GmbH,
Hoechberg, Germany). After inhaling salbutamol (Ventolin;
GlaxoSmithKline; London, UK), the forced vital capacity
(FVC), the forced expiratory volume in one second
(FEV1), and FEV1/FVC ratio were obtained. In the sub-
jects with FEV1/FVC< 0.70, FEV1 ≥ 80% predicted were
classified as mild COPD; 50% ≤ FEV1 < 80% predicted were
moderate COPD; 30% ≤ FEV1 < 50% predicted were severemild-to-moderate and severe COPD groups
rate COPD group (n = 37) Severe COPD group (n = 48) P Value






33.09 ± 8.11 34.13 ± 5.52 0.95a
29.00 ± 6.60 32.64 ± 7.81 0.22a
9.49 ± 4.75 9.42 ± 4.01 0.35a
22.11 ± 3.66 21.91 ± 3.29 0.73a
54.05 54.17 0.34b
r diseases include hypertension, coronary artery disease and congestive heart
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Mild and moderate COPD patients were defined as mild-
to-moderate COPD group, while severe and very severe
COPD patients were defined as severe COPD group [21].
Cognitive ability tests
Cognitive function was measured using the MMSE Test,
which is the most commonly used screening test for
cognitive impairment. This instrument explores spatial
and temporal orientation, short- and long-term verbal
memory, attention, verbal attention, and practical ability
in 12 items and 30 questions. The correct answers to one
question gives 1 score point (total from 0 to 30). A scoreFigure 1 MRI images from a control subject, a mild-to-moderate COP
the region of the hippocampus in one hemisphere. A = control subject; B =
right hippocampus of control subject; AL = the left hippocampus of contro
patient; BL = the left hippocampus of mild-to-moderate COPD patient; CR = th
of severe COPD patient.less than 24 indicated a mild cognitive impairment. All
examinations were performed by a trained neuropsychologist.
Measurement of serum S100B concentration
Blood samples (3 ml) were collected by venipuncture with
a tube without anticoagulants around 6.30 a.m. in a regu-
lar exanimation. Serum was obtained by centrifugation at
3000 rpm for 10 min, and then frozen at −70°C until stu-
died. Serum S100B concentrations were measured using a
commercial enzyme-linked immunosorbent assay (ELISA)
kit (RD192090100R, BioVendor, Brno, Czech Republic)
according to the manufacturer’s instructions. The intra-
assay and inter-assay variation coefficients were 3.3% andD patient and a severe COPD patient. A line has been placed over
mild-to-moderate COPD patient; C = severe COPD patient; AR = the
l subject; BR = the right hippocampus of mild-to-moderate COPD
e right hippocampus of severe COPD patient; CL = the left hippocampus
Table 2 Clinical characteristics, hippocampal volume and serum S100B concentration in the control and COPD groups
Test parameter Control group (n = 31) Mild-to-moderate COPD group (n = 37) Severe COPD group (n = 48) P Value
FEV1, % predicted 106.10 ± 15.14 61.14 ± 6.35
* 34.15 ± 8.89*,+ <0.01
FVC, % predicted 94.85 ± 14.40 76.80 ± 10.42* 54.13 ± 14.93*,+ <0.01
FEV1/ FVC 90.07 ± 7.97 61.89 ± 6.27
* 49.85 ± 10.47*,+ <0.01
PaO2, mmHg 91.82 ± 6.95 71.89 ± 6.94
* 66.36 ± 11.83* <0.01
PaCO2, mmHg 37.00 ± 2.72 40.27 ± 6.53 48.27 ± 10.61
*,+ <0.01
SaO2, % 97.50 (97.00-97.90)
a 92.15 ± 2.86* 90.45 (84.80, 93.73)a,* <0.01b
Rt hippocampus, cm3 3.43 ± 0.59 2.56 ± 0.31* 2.37 ± 0.38* <0.01
Lt hippocampus, cm3 3.41 ± 0.47 2.45 ± 0.29* 2.33 ± 0.29* <0.01
Tl hippocampus, cm3 6.84 ± 1.01 5.01 ± 0.49* 4.69 ± 0.57* <0.01
ICV, cm3 1323.84 ± 112.37 1296.85 ± 111.35 1280.47 ± 130.17 >0.05
MMSE score 28.00(27.00-29.00)a 24.57 ± 2.24* 22.15 ± 2.88*,+ <0.01b
S100B, pg/ml 60.88 ± 8.43 77.02 ± 9.72* 105.70 ± 13.30*,+ <0.01
Data are presented as means ± SD. P value: One-way analysis of variance, except where indicated otherwise. *P <0.01 vs. control group; +P < 0.01 vs. mild-to-
moderate group. a: Medians (interquartile range). b: Kruskal-Wallis test.
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; PaO2 = arterial oxygen tension; PaCO2 = arterial carbon dioxide tension; SaO2 = blood
oxygen saturation; MMSE =mini mental state exam; Rt = right; Lt = left; Tl = total; ICV = intracranial volume.
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The limit of detection is 15 pg/ml.
Magnetic resonance imaging
All MRI studies were performed on a 3.0-Tesla supercon-
ducting system (Trio, Tim, VB15, Sciemens, Erlangen,
Germany). T1-weighted MRI scans were collected using a
three dimensional (3D) magnetization prepared rapid gra-
dient echo (MP-RAGE) sequence for each subject, using
the following parameters: TE/TR = 5.5/1.5; flip angle = 30;
matrix size = 256 × 256; slice thickness = 1.4 mm; slices =
248. The total scan time was 2 minutes and 56 seconds.Figure 2 Box plot of the hippocampal volumes in control group and
through each box represents the median. The ends of each box represent
range of the date. The cross of each box represents the mean.* * P < 0.01.Volumetric measurement
Volumetric measurements were performed with a semi-
automated software package in the Department of Radio-
logy, First Affiliated Hospital of Anhui Medical University.
The MRI images were transferred to ADM workstation
(version 4.4). In this study, the contours of hippocampus
were manually outlined by two experienced raters blinded
to participants’ age, sex and diagnosis to insure consistency.
Boundary definition for hippocampus was according to
well-established protocol [22]. Relevant images from stand-
ard atlases were referred to ensure a consistent reference to
the boundaries and landmarks for hippocampus. Once themild-to-moderate and severe COPD groups. The horizontal line
the 25th and 75th percentile locations, and the lines represent the
Table 3 Relationships between the relative test values















volume (n = 85)
r P r P r P
PaO2 0.55 <0.01 0.40 <0.01 0.51
a <0.01
PaCO2 0.15 NS −0.14 NS −0.15
a NS
SaO2 0.35 <0.05 0.19
a NS 0.29a <0.01
FVC 0.13 NS 0.01 NS 0.21 <0.05
FEV1 0.14 NS −0.12 NS 0.22
a <0.05
FEV1/FVC −0.05 NS −0.09 NS 0.10
a NS
MMSE 0.47 <0.01 0.19 NS 0.36 <0.01
S100B −0.24 NS −0.15 NS −0.33 <0.01
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity;
PaO2 = arterial oxygen tension; PaCO2 = arterial carbon dioxide tension;
SaO2 = blood oxygen saturation; MMSE =mini mental state exam; NS = no
significant correlations. r = Pearson Correlation coefficient (except where
indicated otherwise); a: Spearman rank correlation coefficient.
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ume was calculated by multiplying the area outlined by
slice thickness. The total hippocampal volume was then cal-
culated by adding the slice volumes. The interrater reliabi-
lity of the volume measurements was determinate by the
intraclass correlation coefficients (ICC) [23]. The ICC for
the right and left hippocampus were 0.96 and 0.97, respect-
ively. Normalization of the original hippocampal volume
with intracranial volume (ICV) was carried out using the
method described by Jack CR Jr et al. [24].Statistical analysis
Categorical variables were compared using a chi-squared
test. Statistical significance of the differences between mean
values was tested using one-way analysis of variance for
variables with normal distribution and a Kruskal-Wallis test
otherwise. A Bonferroni correction for multiple com-
parisons was applied. The Pearson Correlation analyses
were used to verify the relationship between numerical
variables with normal distribution, while the Spearman
correlation test was applied to nonparametric variables.
All statistical analyses were performed using Graph-
pad Prism5. Values of p < 0.05 were considered to be
significant.Results
Demographic characteristics in the control group and
COPD groups
Demographic characteristics of the control, the mild-to-
moderate and the severe COPD groups are depicted in
Table 1. The three groups were statistically similar withrespect to age, sex, smoking, education level, BMI and
cardiovascular disease (P > 0.05).
The alterations of the hippocampal volumes and serum
S100B level in COPD patients
As shown in Figure 1, hippocampal atrophy was seen in
the mild-to-moderate and severe COPD patients when
compared with control subjects.
Table 2 and Figure 2 show that both the right and
left hippocampal volumes were significantly smaller in
the mild-to-moderate (right P < 0.01, left P < 0.01) and
severe COPD (right P < 0.01, left P < 0.01) groups com-
pared to the control group. However, there was no signifi-
cant difference between the mild-to-moderate COPD
group and severe COPD group (P > 0.05).
Table 2 also shows that the serum S100B levels increased
significantly in the mild-to-moderate (P < 0.01) and severe
COPD (P < 0.01) groups compared with the control group.
Furthermore, the serum S100B concentration was signifi-
cantly higher in the severe COPD group than that in the
mild-to-moderate COPD group (P < 0.01).
The cognitive impairment in COPD patients
Table 2 shows that the MMSE score was significantly lower
in the mild-to-moderate (P < 0.01) and severe COPD (P <
0.01) groups compared with the control group. Moreover,
the MMSE score was significantly lower in the severe COPD
group than in the mild-to-moderate COPD group (P < 0.01).
Correlations between hippocampal volumes and
relevant factors
Table 3 shows the correlation between the hippocampal
volume, pulmonary function parameters, arterial blood
gases, MMSE scores and serum S100B levels in COPD pa-
tients. The hippocampal volume was positively correlated
with the MMSE scores, PaO2 and SaO2 (r = 0.47, P < 0.01;
r = 0.55, P < 0.01; r = 0.35, P < 0.05, respectively) (Figure 3A
and Figure 3C) in the mild-to-moderate COPD group,
while it was positively associated with PaO2 (r = 0.46,
P < 0.01) in the severe COPD group (Figure 3D). Further-
more, it was also positively associated with the MMSE
scores (r = 0.36, P < 0.01) and negatively correlated with
S100B levels (r = −0.33, P < 0.01) in the total COPD pa-
tients (Figure 3B).
Correlations between cognitive function and relevant factors
Table 4 shows the correlation between MMSE scores, pul-
monary function parameters, arterial blood gases and the
concentrations of serum S100B in COPD patients. The
MMSE score was positively associated with PaO2 (r = 0.59,
P < 0.01) and negatively correlated with serum S100B con-
centration ((r = −0.40, P < 0.05) in the mild-to-moderate
COPD group, while it was positively associated with PaO2,
SaO2 and FEV1 (r = 0.46, P < 0.01; r = 0.37, P < 0.01; r =
Figure 3 Pearson correlations between the volumes of hippocampus and relevant factors in COPD groups. ● =MMSE scores;▼ = serum S100B
concentrations;▲= PaO2; ■= SaO2. A=mild-to-moderate COPD group: MMSE (r = 0.47, P < 0.01). B= total COPD patients: MMSE (r = 0.36, P < 0.01); S100B
(r =−0.33, P < 0.01). C=mild-to-moderate COPD group: PaO2 (r = 0.55, P < 0.01); SaO2 (r = 0.35, P < 0.05). D= severe COPD group: PaO2 (r = 0.40, P < 0.01).
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with S100B (r = −0.31, P < 0.05) in the severe COPD
group (Figure 4).
Discussion
In the present study, we measured hippocampal volume
and found hippocampal atrophy by MRI in COPD pa-
tients. This observation shows for the first time that
structural alteration of the hippocampus may be in-
volved in the cognitive impairment in COPD. Further-
more, we evaluated the serum S100B concentration and
found that it is higher in COPD patients compared with
that in control subjects.Structural magnetic resonance imaging is the most cli-
nical approach used to detect brain abnormalities in indivi-
duals who might be at risk for Alzheimer’s disease and
MCI [12,25,26]. Recent studies have reported that hippo-
campal atrophy can be used as a biomarker for cognitive
dysfunction and the rate of hippocampal atrophy was
significantly correlated with the cognitive function in
Alzheimer’s disease [13]. To our knowledge, quantita-
tive assessment of the hippocampal region in COPD
patients has not yet been carried out. In our previous
study, we observed an association between cognitive
decline and the classification of severity during disease
progression in COPD patients [9]. In the present study,
Table 4 Relationships between the relative test values













r P r P r P
PaO2 0.59 <0.01 0.46 <0.01 0.54
a <0.01
PaCO2 0.12 NS −0.11 NS −0.16
a NS
SaO2 0.21 NS 0.37
a <0.01 0.36a <0.01
FVC 0.18 NS 0.17 NS 0.39 <0.01
FEV1 0.25 NS 0.35 <0.05 0.49
a <0.01
FEV1/FVC 0.03 NS 0.13 NS 0.31
a <0.05
S100B −0.40 <0.05 −0.31 <0.05 −0.52 <0.01
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity;
PaO2 = arterial oxygen tension; PaCO2 = arterial carbon dioxide tension; SaO2 =
blood oxygen saturation; MMSE =mini mental state exam; NS = no significant
correlations. r = Pearson Correlation coefficient (except where indicated
otherwise); a: Spearman rank correlation coefficient.
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that accounts for cognitive impairment in COPD patients.
Therefore, we measured hippocampal volume in patients
with different severity of COPD. Surprisingly, we found
that hippocampal atrophy did occur in COPD patients
and there were significant correlations with PaO2, SaO2
and MMSE which may account for cognitive decline in
COPD patients. However, the mechanism is poorly unders-
tood. One possible explanation is that COPD patients exist
in a state of low-grade systemic inflammation [3] and per-
sistent airflow limitation which leads to chronic hypoxemia.
Chronic hypoxemia is a major mechanism that can ad-
versely affect cognitive performance and hippocampal
volume [27-30]. In this study, we also examined the re-
lationships between hippocampal volume and relevant
factors in mild-to-moderate and severe COPD groups,
respectively. We found that hippocampal volume was po-
sitively correlated with the level of PaO2 in both mild-to-
moderate and severe COPD groups. In addition, it was
positively associated with SaO2 in mild-to-moderate COPD
group. These findings show that the chronic hypoxemia in
COPD patients may induce hippocampal atrophy, which
plays a crucial role in cognitive impairment.
Interestingly, our present findings show that there were
no significant differences of hippocampal volumes be-
tween mild-to-moderate and severe COPD groups. One
possible explanation is that the cumulative loss of neurons
and their connections results in hippocampal atrophy in
the early stage of the disease, while the structural change
converts to the functional deterioration in the later stage.
In addition, as we investigated the associations between
hippocampal volume and cognitive function in COPD
groups, we found that the hippocampal volume is posi-
tively correlated with cognitive ability in mild-to-moderateCOPD patients. However, this was not shown in the se-
vere COPD group. One possible explanation is that other
regions of brain, such as transentorhinal, parahippocampal
gyrus and entorhinal cortexes, which also play a critical
role in the neural control of cognitive function [31],
may also be affected by hypoxemic insults and systemic
inflammatory stress with the progress of the disease.
Therefore, there was no lineary correlation between hip-
pocampal atrophy and cognitive impairment in the later
stage of the disease.
S100B is a 21 kDa calcium binding protein produced and
released primarily by astrocytes [32], which has been inves-
tigated as a biochemical marker of central nervous system
injury. Previous studies have demonstrated that S100B
could exert neurotrophic or neurotoxic effects depend-
ing on its concentration. High S100B concentration can
be detrimental. It has been proposed that S100B may be
the “CRP (C-reactive protein) of the brain” [14]. Some pre-
vious studies have showed that the levels of serum S100B
were significant higher in patients with obstructive sleep
apnea syndrome (OSAS) or Alzheimer’s disease [16,33]. In
the present study, we evaluated the serum S100B con-
centration and found that it is higher in COPD patients
compared with that in control subjects. One possible
explanation is that changes in hippocampal structure
and volume appear to arise from a reduction in neural
processes and synapses, rather than from neuronal loss.
However, future studies are needed to address the pre-
cise mechanisms underlying this observation.
Finally, we observed an association between cognitive
decline and the classification of severity during disease
progression in COPD patients and the level of PaO2 was
positively correlated with cognitive ability. This observed
cognitive impairment and relevant factors in COPD are
in agreement with our previous report [9]. These fin-
dings suggest that the chronic hypoxemia plays a key role
in the cognitive impairment in COPD patients.
A limitation of this study is the relatively small size of
the participant population, which may partially account
for the weak association between some of the measure-
ments in our results. While the number of cases will be
continuously increased in our future study, we anticipate
that this study will lead to the realization of cognitive
impairment and some structural abnormalities of brain
in COPD patients in the field. Second, other brain regions,
especially the entorhinal cortex, transentorhinal and para-
hippocampal gyrus which also play a critical role in the
neural control of cognitive function need to be examined.
Third, the MMSE, which has proven useful and sufficient
for cognitive measurements, provides a broad scale and
does not include measures of executive function. A
neuropsychological testing battery will have to be consi-
dered in future studies to provide detailed analysis and
quantification of cognitive functions of patients. Nonetheless,
Figure 4 Pearson correlations between MMSE scores and relevant factors in COPD groups.▼= serum S100B concentrations;▲=PaO2;
◆= FEV1% predicted. A=mild-to-moderate COPD group: S100B (r =−0.40, P < 0.01); B= severe COPD group: S100B (r =−0.31, P < 0.01); C=mild-to-moderate
COPD group: PaO2 (r = 0.59, P < 0.01); D = severe COPD group: PaO2 (r = 0.46, P < 0.01); FEV1 (r = 0.35, P < 0.05).
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ing studies may be useful in identifying COPD patients
who are at increased risk of cognitive impairment.
Given the significant clinical implications of this
study, further studies are needed to gain much more
insight into this problem. The application of neuro-
psychological tests which is designed for quantifying
specific parameters of certain mental function, such as
visual memory, verbal fluency, and visuospatial deserve
testing in COPD. Meanwhile, some brain regions, such
as the entorhinal cortex, transentorhinal and parahip-
pocampal gyrus critical for cognitive function need fur-
ther explorations.Conclusions
In conclusion, hippocampal atrophy which leads to cogni-
tive dysfunction does occur in COPD. MRI based quanti-
tative assessment of the hippocampus provides direct
evidence that COPD patients exhibit cognitive impair-
ment. The most prevalent mechanism accountable for
hippocampal atrophy in COPD patients is chronic hypox-
emia. Higher serum S100B level may be the peripheral
biochemical marker for cognitive impairment in COPD.
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